Stryker's Q1 net sales, spine and orthopedic revenue climb since 2019: A 3-year comparison

Carly Behm -   Print  |
Listen

Despite the COVID-19 pandemic, Stryker continued financial growth and has posted gains in its spine and neurotechnology segment since 2019. While the orthopedic segment has grown overall since 2019, the increase was most apparent in trauma and extremities sales.

Here's a year-over-year comparison of Stryker's first-quarter performance in the last three years:

Q1 2021
Net sales: $4 billion
Spine and neurotechnology sales: $848 million
Total orthopedic sales: $1.5 billion
Knee sales: $412 million
Hip sales: $309 million
Trauma sales: $640 million

Q1 2020
Net sales: $3.6 billion
Spine and neurotechnology sales: $744 million
Total orthopedic sales: $1.2 billion
Knee sales: $432 million
Hip sales: $316 million
Trauma sales: $392 million

Q1 2019
Net sales: $3.5 billion
Spine and neurotechnology sales: $739 million
Total orthopedic sales: $1.3 billion
Knee sales: $439 million
Hip sales: $336 million
Trauma sales: $396 million

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers

Featured Podcast